<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01324908</url>
  </required_header>
  <id_info>
    <org_study_id>VICC CTT 1063</org_study_id>
    <secondary_id>NCI-2011-00225</secondary_id>
    <nct_id>NCT01324908</nct_id>
  </id_info>
  <brief_title>Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis</brief_title>
  <official_title>T-regulatory Homing Subsets as a Predictor of Response in GVHD Treated With Extracorporeal Photopheresis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies biomarkers in predicting response in patients with&#xD;
      graft-versus-host disease (GVHD) undergoing extracorporeal photopheresis (ECP). ECP treats&#xD;
      the patient's blood with ultraviolet light outside the body and kills the white blood cells&#xD;
      before returning blood back into the patient's body. Studying samples of blood from patients&#xD;
      with GVHD may help doctors identify and learn more about biomarkers related to GVHD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To show that extracorporeal photopheresis (ECP)increases skin and gut homing T regulatory&#xD;
      (T-reg) cells in patients with GVHD clinically responding to ECP.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Response rates of GVHD with extracorporeal photopheresis(ECP)as measured by NIH response&#xD;
      criteria&#xD;
&#xD;
      II. Incidence of T-reg cell frequency(%)with various NIH subtypes of chronic&#xD;
      graft-versus-host disease (GVHD)&#xD;
&#xD;
      III. Incidence of T-reg homing subsets(%)with various NIH subtypes of chronic&#xD;
      graft-versus-host disease (GVHD)&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8&#xD;
      weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 2, 4, and 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 16, 2020</completion_date>
  <primary_completion_date type="Actual">July 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Association of frequency of skin and gut homing Tregs (%) in patients with chronic GVHD with response to ECP.</measure>
    <time_frame>6 months after last patient is on study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates of GVHD with ECP as measured by NIH response criteria</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of T-reg cell frequency (%) with various NIH subtypes of chronic GVHD</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of T-reg homing subsets (%) with various NIH subtypes of chronic GVHD</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Graft Versus Host Disease (GVHD)</condition>
  <arm_group>
    <arm_group_label>Treatment (Treg predictor of response to ECP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>extracorporeal photopheresis</intervention_name>
    <description>Undergo ECP</description>
    <arm_group_label>Treatment (Treg predictor of response to ECP)</arm_group_label>
    <other_name>extracorporeal photophoresis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (Treg predictor of response to ECP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with any NIH subtype of chronic GVHD that is being treated with ECP&#xD;
&#xD;
          -  Karnofsky Performance Scale (KPS) &gt; 60% at time of study enrollment&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Steroid dose not greater than 2 mg/kg prednisone equivalent at time of study&#xD;
             enrollment&#xD;
&#xD;
          -  If patient has steroid refractory GVHD (defined as worsening of GVHD after 3 days of 2&#xD;
             mg/kg prednisone equivalent or no improvement after 7 days of 2 mg/kg prednisone&#xD;
             equivalent), time interval from start of steroids to initiation of ECP should not be &gt;&#xD;
             14 days&#xD;
&#xD;
          -  No use of an investigational agent within 2 weeks of starting ECP&#xD;
&#xD;
          -  No uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus [CMV]&#xD;
             viremia is permitted)&#xD;
&#xD;
          -  No evidence of relapse or progression of underlying disease (molecular evidence of&#xD;
             relapse/progression or mixed chimerism is permitted)&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) should be willing to use 2 forms of&#xD;
             contraception; male patients should be willing to use contraception&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are breastfeeding or pregnant&#xD;
&#xD;
          -  Patients known to be human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Bronchiolitis obliterans as the sole indication of ECP&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study&#xD;
&#xD;
          -  Mechanical ventilation, renal replacement therapy, admitted in intensive care until at&#xD;
             time of enrollment&#xD;
&#xD;
          -  Stage 4 gastrointestinal GVHD as per Seattle-Glucksberg criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madan Jagasia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Michael Byrne</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

